Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. Liu S, et al. Among authors: hsu ec. Cell Rep Med. 2024 Feb 20;5(2):101381. doi: 10.1016/j.xcrm.2023.101381. Epub 2024 Jan 19. Cell Rep Med. 2024. PMID: 38244540 Free PMC article.
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu EC, Liu S, Bermudez A, Kanchustambham V, Shankar V, Inde Z, Alabi BR, Muruganantham A, Shen M, Pandrala M, Nolley R, Aslan M, Ghoochani A, Agarwal A, Buckup M, Kumar M, Going CC, Peehl DM, Dixon SJ, Zare RN, Brooks JD, Pitteri SJ, Malhotra SV, Stoyanova T. Rice MA, et al. Among authors: hsu ec. Cell Rep Med. 2022 Feb 2;3(2):100502. doi: 10.1016/j.xcrm.2021.100502. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35243415 Free PMC article.
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
Shen M, Liu S, Toland A, Hsu EC, Hartono AB, Alabi BR, Aslan M, Nguyen HM, Sessions CJ, Nolley R, Shi C, Huang J, Brooks JD, Corey E, Stoyanova T. Shen M, et al. Among authors: hsu ec. Br J Cancer. 2023 Nov;129(11):1818-1828. doi: 10.1038/s41416-023-02448-y. Epub 2023 Oct 5. Br J Cancer. 2023. PMID: 37798372 Free PMC article.
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Hsu EC, Rice MA, Bermudez A, Marques FJG, Aslan M, Liu S, Ghoochani A, Zhang CA, Chen YS, Zlitni A, Kumar S, Nolley R, Habte F, Shen M, Koul K, Peehl DM, Zoubeidi A, Gambhir SS, Kunder CA, Pitteri SJ, Brooks JD, Stoyanova T. Hsu EC, et al. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2032-2042. doi: 10.1073/pnas.1905384117. Epub 2020 Jan 13. Proc Natl Acad Sci U S A. 2020. PMID: 31932422 Free PMC article.
Plectin is a regulator of prostate cancer growth and metastasis.
Buckup M, Rice MA, Hsu EC, Garcia-Marques F, Liu S, Aslan M, Bermudez A, Huang J, Pitteri SJ, Stoyanova T. Buckup M, et al. Among authors: hsu ec. Oncogene. 2021 Jan;40(3):663-676. doi: 10.1038/s41388-020-01557-9. Epub 2020 Nov 20. Oncogene. 2021. PMID: 33219316 Free PMC article.
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. Liu S, et al. Among authors: hsu ec. Sci Rep. 2024 Jan 4;14(1):486. doi: 10.1038/s41598-023-50215-z. Sci Rep. 2024. PMID: 38177207 Free PMC article.
42 results